Diabetic retinopathy

January 8, 2018

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-lipoic acid, Epicatechin and Marine (LAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 8/January/2018, 10.56 pm

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-lipoic acid, Epicatechin and Marine (LAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 8/January/2018, 10.56 pm https://genomediscovery.org/wp-content/uploads/2018/01/α-Lipoic-acid-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/α-Lipoic-acid-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity1.jpg January 8, 2018 January 8, 2018

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

January 7, 2018

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Efonidipine, Epicatechin and Marine (EPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 7/January/2018, 11.40 pm

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Efonidipine, Epicatechin and Marine (EPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 7/January/2018, 11.40 pm https://genomediscovery.org/wp-content/uploads/2018/01/Efonidipine-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Efonidipine-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity.jpg1_.jpg January 7, 2018 January 7, 2018

January 7, 2018

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fimasartan, Epicatechin and Marine (FSEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 7/January/2018, 10.55 pm

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fimasartan, Epicatechin and Marine (FSEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 7/January/2018, 10.55 pm https://genomediscovery.org/wp-content/uploads/2018/01/Fimasartan-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity2.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Fimasartan-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration-attenuates-insulin-resistance-and-cardiac-ageing-and-thereby-promotes-longevity2.jpg2_.jpg January 7, 2018 January 7, 2018

January 6, 2018

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing t-AUCB, Epicatechin and Marine (t-AUCBEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 6/January/2018, 11.18 pm

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing t-AUCB, Epicatechin and Marine (t-AUCBEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 6/January/2018, 11.18 pm https://genomediscovery.org/wp-content/uploads/2018/01/TAUCBEM-inhibits-EPHX2.sEH1-expression-decreases-DHDP-levels-promotes-pericite-viability-inhibits-vascular-permeability-prevents-diabetic-retinopathy.jpg1_.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/TAUCBEM-inhibits-EPHX2.sEH1-expression-decreases-DHDP-levels-promotes-pericite-viability-inhibits-vascular-permeability-prevents-diabetic-retinopathy.jpg1_.jpg2_.jpg January 6, 2018 January 6, 2018

January 5, 2018

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing TPPU, Epicatechin and Matrine (TPPUEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 11.48 am

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing TPPU, Epicatechin and Matrine (TPPUEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 11.48 am https://genomediscovery.org/wp-content/uploads/2018/01/TPPUEM-inhibits-EPHX2-and-attenuates-diabetic-retinopathy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/TPPUEM-inhibits-EPHX2-and-attenuates-diabetic-retinopathy.jpg January 5, 2018 January 5, 2018

January 3, 2018

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Astaxanthin, Epicatechin and Matrine (AEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/January/2018, 9.55 am

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Astaxanthin, Epicatechin and Matrine (AEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/January/2018, 9.55 am https://genomediscovery.org/wp-content/uploads/2018/01/AEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-and-attenuates-the-development-of-diabetic-retinopathy1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/AEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-and-attenuates-the-development-of-diabetic-retinopathy1.jpg January 3, 2018 January 3, 2018

Popular Post